A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors
This clinical trial is testing a new study drug called BGB-58067, both on its own and with standard cancer treatments, in people with advanced solid tumors. Researchers want to see if the treatment is safe, how it affects the body, and if it can help fight tumors that have a specific genetic feature.
You might be able to join if you have an advanced solid tumor that tests positive for a specific genetic change involving the loss of MTAP, and you are well enough to go about your daily life. However, people who have had certain previous targeted treatments or specific serious health complications cannot participate.
If you join, you will receive the investigational study drug BGB-58067, and your doctors will closely monitor your health and how your cancer responds to the treatment. You will also need to provide a tissue sample from your tumor for genetic testing.
The study is currently recruiting patients at locations in California and Florida. It is an active trial looking for eligible participants.
- 1Testing a new investigational medication called BGB-58067 for advanced solid tumors.
- 2Requires a specific genetic feature in the cancer cells known as MTAP deficiency.
- 3Currently recruiting patients at medical centers in California and Florida.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.